Compounders Research Compare

Rezolute, Inc.(RZLT)

Biotechnology · Redwood City, CA

$4.32-0.01 (-0.23%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Rezolute, Inc.

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Redwood City, CA

58 employees

www.rezolutebio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Nevan Charles Elam

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T21:42:57.043Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:42:57.043Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 415,982,736
TTM free cash flow · period ending 2026-06-30: -64,635,000

FMP input reference: eb6c183c54b52a3f5be7b88cd35f52a8db6123751fb387d2cb2c86d403628cdc

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RZLT Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

RZLT Competitors' Price/FCF Ratio

Rezolute, Inc.

Current

Market Cap

$415.98M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Senseonics Holdings, Inc.

Market Cap

$416.27M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Editas Medicine, Inc.

Market Cap

$418.95M

Price/FCF Ratio

N/A

TTM Avg

53.84

3Y Avg

53.84

5Y Avg

53.84

Prothena Corporation plc

Market Cap

$419.87M

Price/FCF Ratio

N/A

TTM Avg

44.26

3Y Avg

44.26

5Y Avg

44.26

MapLight Therapeutics, Inc.

Market Cap

$411.21M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Strata Critical Medical, Inc.

Market Cap

$411.00M

Price/FCF Ratio

N/A

TTM Avg

198.72

3Y Avg

198.72

5Y Avg

198.72

Tilray Brands, Inc.

Market Cap

$422.72M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Tectonic Therapeutic, Inc.

Market Cap

$422.86M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NeoGenomics, Inc.

Market Cap

$424.10M

Price/FCF Ratio

N/A

TTM Avg

53.25

3Y Avg

37.33

5Y Avg

28.89

Eikon Therapeutics, Inc. Common Stock

Market Cap

$406.58M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Rezolute, Inc. (RZLT)	$415.98M	N/A	N/A	N/A	N/A
Senseonics Holdings, Inc. (SENS)vs ›	$416.27M	N/A	N/A	N/A	N/A
Editas Medicine, Inc. (EDIT)vs ›	$418.95M	N/A	53.84	53.84	53.84
Prothena Corporation plc (PRTA)vs ›	$419.87M	N/A	44.26	44.26	44.26
MapLight Therapeutics, Inc. (MPLT)vs ›	$411.21M	N/A	N/A	N/A	N/A
Strata Critical Medical, Inc. (SRTA)vs ›	$411.00M	N/A	198.72	198.72	198.72
Tilray Brands, Inc. (TLRY)vs ›	$422.72M	N/A	N/A	N/A	N/A
Tectonic Therapeutic, Inc. (TECX)vs ›	$422.86M	N/A	N/A	N/A	N/A
NeoGenomics, Inc. (NEO)vs ›	$424.10M	N/A	53.25	37.33	28.89
Eikon Therapeutics, Inc. Common Stock (EIKN)vs ›	$406.58M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics